Analysts have been eager to weigh in on the Healthcare sector with new ratings on aTyr Pharma (LIFE – Research Report) and Pfizer (PFE – Research Report).
Pfizer (PFE)
In a report released today, Trung Huynh from UBS maintained a Hold rating on Pfizer, with a price target of $34.00. The company’s shares closed last Tuesday at $29.82.
According to TipRanks.com, Huynh is ranked #665 out of 8565 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $39.91 average price target, representing a 31.8% upside. In a report issued on October 16, Wells Fargo also maintained a Hold rating on the stock with a $35.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LIFE:
